2013 Fiscal Year Final Research Report
Interleukin-6 (IL-6) receptor antibody therapy to malignant pleural mesothelioma
| Project/Area Number |
23592077
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HASEGAWA Seiki 兵庫医科大学, 医学部, 教授 (10252438)
KONDOU Nobuyuki 兵庫医科大学, 医学部, 講師 (50402889)
NISHIMOTO Norihiro 東京医科大学, 医学部, 教授 (80273663)
TAKUWA Teruhisa 兵庫医科大学, 医学部, 助教 (00412049)
KURODA Ayumi 兵庫医科大学, 医学部, 助教 (90642570)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 悪性胸膜中皮腫 |
|---|
| Research Abstract |
Interleukin-6 (IL-6) is associated with rheumatoid arthritis. Tocilizumab (Actemra : a humanized anti-IL-6R antibody) is used for rheumatoid arthritis therapy. We investigated the effect of tocilizumab to malignant pleural mesothelioma. Tocilizumab suppressed malignant pleural mesothelioma cell growth and reductions were 10-25%. We compared the combination effect of pemetrexed, cisplatin and tocilizumab. The combination of pemetrexed, cisplatin and tocilizumab was more effective than any other two drugs combinations. We have already conformed the effect of MEK inhibitor. We checked the combination effect of tocilizumab and MEK inhibitor. The combination of tocilizumab and MEK inhibitor suppressed malignant pleural mesothelioma cell growth more than a single administration of MEK inhibitor. Tocilizumab reduced the phosho-Stat3 expression to 1/3-1/5. The combination of tocilizumab and MEK inhibitor reduced more the phosho-Stat3 expression.
|
